Pfizer receives backing for late-stage trial of kidney cancer drug in Asia
The study will focus on patients at high risk of recurrent renal cell carcinoma following a nephrectomy, or removal of the kidneys. Pfizer, based in New York, is seeking Food and Drug Administration approval to market the drug for advanced renal cell ...
SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for ...Sacramento Bee
Pfizer Teams with SFJ on Phase III Study of Axitinib in AsiaGenetic Engineering News

all 50 news articles »